Renal artery stenosis resident survival guide: Difference between revisions
Jump to navigation
Jump to search
Line 22: | Line 22: | ||
{{familytree/start}} | {{familytree/start}} | ||
{{familytree | | | A01 | | | A01= ❑ '''Determine if one or more of the above is present'''}} | {{familytree | | | A01 | | | A01= ❑ '''Determine if one or more of the above is present'''}} | ||
{{familytree | | | | | | | |!| | | }} | {{familytree | | | | | | | |!| | | | | | | }} | ||
{{familytree | | | A02 | | A02= <table class="wikitable"> | {{familytree | | | A02 | | A02= <table class="wikitable"> | ||
<tr class="v-firstrow"><th>Scenario</th><th>Level of evidence</th></tr> | <tr class="v-firstrow"><th>Scenario</th><th>Level of evidence</th></tr> | ||
<tr><td>'''1.'''Onset of hypertension before the age of 30 years or severe hypertension after the age of 55</td><td>Class I; LOE B</td></tr> | <tr><td>'''1.'''Onset of hypertension before the age of 30 years or severe hypertension after the age of 55</td><td>Class I; LOE B</td></tr> | ||
<tr><td>2. Accelerated, resistant, or malignant hypertension</td><td>Class I; LOE C</td></tr> | <tr><td>2. Accelerated, resistant, or malignant hypertension</td><td>Class I; LOE C</td></tr> | ||
<tr><td>3. Development of new azotemia or worsening renal function after administration of an ACE inhibitor or ARB agent</td><td>Class I; LOE B</td></tr> | <tr><td>3. Development of new azotemia or worsening renal function after administration of an ACE inhibitor or ARB agent</td><td>Class I; LOE B</td></tr> |
Revision as of 05:59, 6 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Karol Gema Hernandez, M.D. [2]
Definition
This section provides a short and straight to the point definition of the disease or symptom in one sentence.
Causes
Life Threatening Causes
Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.
Common Causes
Clinical Clues to the Diagnosis of RAS
❑ Determine if one or more of the above is present | |||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||
Risk <1% | Risk >1% | ||||||||||||||||||||||||||||||
❑ Do not monitor platelet count | ❑ Monitor platelet count every 2 or 3 days from day 4 to day 14 (or until heparin is stopped) | ||||||||||||||||||||||||||||||
Algorithm based on the 2012 ACCP evidence based clinical practice guidelines.[1]
References
- ↑ Linkins LA, Dans AL, Moores LK, Bona R, Davidson BL, Schulman S; et al. (2012). "Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines". Chest. 141 (2 Suppl): e495S–530S. doi:10.1378/chest.11-2303. PMC 3278058. PMID 22315270.